Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100081 | 0.90 | POLB (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28372338 | 0.89 | USP30 (0.33) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22099917 | 0.83 | MAPT (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22099899 | 0.82 | SMN1; SMN2 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28373358 | 0.82 | SMN1; SMN2 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20764590 | 0.81 | SMN1; SMN2 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20764592 | 0.81 | SMN1; SMN2 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22076743 | 0.81 | NPC1 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22076744 | 0.81 | NPC1 (0.37) | POLBMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22076701 | 0.81 | POLB (0.34) | POLBMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | POLB 2408/4885MAPT 3731/4885NPC1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.